Chronic liver diseases affect millions of people worldwide. By understanding how liver disease progresses, we may be able to identify new therapies that can protect the liver. Dr. Chrystelle Vilfranc studied the role of BRUCE, a protein that is known to be important in several cellular processes in our bodies, in liver disease. She found that the absence of BRUCE in mouse livers led to accelerated liver disease and higher rates of liver cancer when combined with a liver damaging compound. Furthermore, hepatocellular carcinomas that develop in the absence of BRUCE in the liver appear to have increased β-catenin activity. Loss of BRUCE may be a marker of early liver disease in humans, and rescuing BRUCE expression or activity may help stop or reverse disease in the liver.
Dr. Chrystelle Vilfranc received her PhD in Cancer and Cell Biology from the University of Cincinnati. After graduating, she was a 2021 AAAS Mass Media Fellow at the Indianapolis Star. She is now a postdoctoral fellow at Columbia Mailman School of Health, investigating cancer-related population sciences. Her Blog Continue Reading